Cargando…
Stable Expression of Recombinant Factor VIII in CHO Cells Using Methotrexate-Driven Transgene Amplification
Prophylaxis and treatment of inherited clotting disorder hemophilia A requires regular administration of factor VIII. Recombinant factor VIII, which is produced in CHO or BHK cells, is equivalent to the plasma-derived one and is prevalent in current clinical practice in developed countries. Developm...
Autores principales: | Orlova, N. A., Kovnir, S. V., Vorobiev, I. I., Yuriev, A.S., Gabibov, A.G., Vorobiev, A.I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
A.I. Gordeyev
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372988/ https://www.ncbi.nlm.nih.gov/pubmed/22708069 |
Ejemplares similares
-
Blood Clotting Factor VIII: From Evolution to Therapy
por: Orlova, N. A., et al.
Publicado: (2013) -
Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system
por: Orlova, Nadezhda A., et al.
Publicado: (2017) -
A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX
por: Kovnir, S. V., et al.
Publicado: (2018) -
Coagulation Factor IX for Hemophilia B Therapy
por: Orlova, N. A., et al.
Publicado: (2012) -
Improved elongation factor-1 alpha-based vectors for stable high-level expression of heterologous proteins in Chinese hamster ovary cells
por: Orlova, Nadezhda A, et al.
Publicado: (2014)